Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CSJ148 for prevention of HCMV replication in stem cell transplant patients
2014-002150-39Phase 2Completed
- Sponsor
- Novartis
- Start
- Nov 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cytomegalovirus disease (CMV) comparing CSJ148 with Placebo (2 arms). Primary endpoint: Number of participants who require preemptive HCMV therapy. Started Nov 2014; status: completed.
02
Drugs
CSJ148
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on 2014-002150-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002150-39.